European drug panel recommends approval for Novo Nordisk oral diabetes treatment

[January 31, 2020]  (Reuters) - A panel of the European medicines regulator has recommended approving Novo Nordisk's new diabetes pill, Rybelsus, further boosting prospects for the Danish drugmaker with its first-of-a-kind, non-injectable treatment.

The European Medicines Agency said https://www.ema.
europa.eu/en/
medicines/human/
summaries-opinion/rybelsus its human medicines committee adopted a positive opinion on the treatment, chemically called semaglutide, for the treatment of type-2 diabetes - the most common form of the disease.

(Reporting by Pushkala Aripaka in Bengaluru; Editing by Krishna Chandra Eluri)

[© 2020 Thomson Reuters. All rights reserved.]

Copyright 2020 Reuters. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.  Thompson Reuters is solely responsible for this content.